Lin Elizabeth Yeu sold $278K of TARS (indirect holdings)

Lin Elizabeth Yeu (Chief Medical Officer) sold 3,180 indirectly-held shares of Tarsus Pharmaceuticals, Inc. (TARS) at an average of $87.50 ($85.00–$90.00, $0.28M total) across 2 trades on 2026-09-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lin Elizabeth Yeu
Published Sep 9, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TARS
Bearish
medium confidence
Mentioned
$TARS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TARSBearishLow
01

Why it matters

Insider sale of $278K may slightly affect investor perception but limited market impact

02

Market read

Small insider sale; limited trading relevance

03

What to watch

No disclosed reason; could be tax planning or diversification

Relevance 3/10Novelty 4/10Timing: filed Sep 9 2026

Background

Form 4 filing discloses insider transaction for Tarsus Pharmaceuticals

Company-level read

Ticker impact

$TARSBearishMedium confidence
Context

Chief Medical Officer sold 3,180 shares for $278K via 10b5-1 plan

Expected impact

Potential modest downside pressure in near term

Evidence & confidence

Sale size is modest relative to market cap, but CMO insider selling via pre-arranged plan may influence sentiment

Market effects

Minimal impact on biotech sector

None

Low

Counterpoint

Sale may be routine under 10b5-1, not indicative of future performance

Key entities

  • Lin Elizabeth Yeu

    Chief Medical Officer of Tarsus Pharmaceuticals

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TARSHighAI 8/10

Tarsus (TARS) Q3 2026 Earnings Call Transcript

Tarsus (TARS) reported Q3 2026 net product sales of $194.6M for XDEMVY, up 64% YoY. The company raised full-year sales guidance to $715M-$730M. Key growth drivers include increased patient demand, broader ECP prescribing, and retreatment. Tarsus also discussed pipeline progress and acquisition integration.

$TARSMedAI 8/10

Tarsus Pharmaceuticals Q3 Earnings Call Highlights

Tarsus Pharmaceuticals (NASDAQ:TARS) increased its 2026 XDEMVY sales outlook to $715M-$730M, citing stronger demand and advertising returns. Q3 saw 20% sequential growth in high-prescribing eye care professionals. The company expects 2027 direct-to-consumer spending of $80M-$95M. Gross margin is projected at 93%, with SG&A and R&D expenses outlined. Pipeline updates include TP-03 launch in China and upcoming trials for TP-04, TP-05, and IRX-101.